Biogen’s Aduhelm Unites Drug Pricing Advocates

Healthcare purchasers and employers have formed a coalition, EmployersRx, with the goal of convincing House and Senate members to enact drug pricing reform amid Biogen’s Aduhelm approval by the FDA. EmployersRx supports price negotiation by the federal government.

The coalition remarked, “If drug manufacturers know that the FDA will approve drugs with little-to-no value over current treatments, they will lose real incentives to develop truly innovative, lifesaving medications,” adding, “The unprecedented approval and unjustified pricing of aducanumab provides a cautionary tale of a broken system that is in profound need for reform.” Read more here.

(Source: Zachary Brennan, Endpoints News, 6/22/21)